Despite the clinical benefits of CAR-T-cell therapy, 60%–70% of r/r DLBCL patients fail to achieve sustained remission after receiving CD19 CAR-T-cell therapy [3]. Here, CD19 is linked to diffuse large B-cell lymphoma.